Wally A. Omar, MD

My conclusion is: TAVI (whoppingly) superior to SAVR at 1 year in this trial where the heart team decided on type of transcatheter heart valve for their patient. @djc795 @vonBardelebenRS @MattiAdam_MD @PhilippLurz

🔥TELLTALE LBCT results🔥 90 patients at risk of TAVR coronary obstruction enrolled. Primary Endpoints: Efficacy: 100% Safety: 96% Wow! @nih_nhlbi @StFrancis_LI @azeemlatib @JasonFoerst @jamiemccabeMD @djc795 @jeremyrier @AdamGreenbaumMD @CRT_meeting

Had an amazing time at the @OPCILive structural complications course, learning how tips and tricks to get out of some seriously sticky situations. Thank you to @jamiemccabeMD @DrBillLombardi @CathElectroSurg @JasonFoerst @RhianEDavies1 @jeremyrier @CJChungMD

🚨🚨CALL FOR SUBMISSIONS🚨🚨 The American Journal of Cardiology presents our new Applied Clinical Evidence section: an interactive, engaging & informative way to put evidence into practice! sciencedirect.com/journal/the-am… @Updock @HamidNadira @rcstoler @G_Tarantini01 @WallyOmarMD

🚨🚨CALL FOR SUBMISSIONS🚨🚨 The journal has introduced a new section, Applied Clinical Evidence. We encourage you to submit a clinical vignette and engage with your readers in real time, benefitting the cardiology community at large. More info below: sciencedirect.com/journal/the-am…

#TCT2024 #LBCT #EarlyTAVR @PhilGenereuxMD Patients w asymptomatic, severe AS, a strategy of early TAVR compared w clinical surveillance: Resulted in a significant reduction of the PEP: death, stroke, or unplanned CV hospitalization Multiple endpoint variations demonstrated…

EARLY-TAVR at #TCT2024 showed significant benefit of TAVR in asymptomatic patients with severe AS. Presented by @PhilGenereuxMD 👉🏻Asymptomatic patients w/ negative stress test enrolled 👉🏻Median f/u ~4 years 👉🏻Primary endpoint death, stroke, unplanned CV hosp, 50% lower eith TAVR

My main takeaway from RHEIA: The first ever RCT only including women sets the scene for TAVI being the default strategy in female<75 with severe AS🔥🔥! Better access, short hospital stay, faster recovery + excellent clinical and echo outcomes.

A high percentage of patients are unable to undergo a valve-in-valve TAVI procedure due to the high associated risks of sinus sequestration, coronary occlusion, or prevention of future coronary reaccess. The Splitter device, currently under testing, performs leaflet modification…

Edwards Lifesciences buys JenaValve. Four acquisitions in a week finance.yahoo.com/news/edwards-l…

I'm always blown away at the innovative ways in which our colleagues treat patients. Thank you @cvinnovations and the organizers for having me in Denver! #CVI2024

An incredible weekend @OPCILive with thought leaders and innovators in the field, set in a unique format that encouraged discussion and debate. Nothing quite like it. Thank you again to the organizers. #OPCI24

An amazing electrosurgery workshop led by @CathElectroSurg and @OPCILive yesterday. The future of this innovative field is exciting and bright.

The Sideclose technique for #Impella access site bleeding new in @MyJSCAI. Stop the bleeding, keep the Impella! @jason_wollmuth #MCS doi.org/10.1016/j.jsca…

📣 Exciting collaboration alert! #JACC & @TheLancet align to enhance their joint impact on cardiovascular health to better serve patients, readers, and society. bit.ly/3Ux0oHv #Cardiology #GlobalHealth #CVResearch @hmkyale @richardhorton1

Dr. Kearney and I discuss the Short Cut Trial and how it moves the needle from "My best guess" to "here is the best data in real world practice" as this trial evaluates multiple modalities for calcium treatment. #shortcuttrial @kalaswadMD @mbmcentegart @cardiofrizz @rcstoler…

LATE BREAKING news! #TriClip G4 just @FDADeviceInfo approved! Finally both repair and replacement options for our pts #FixTR @hahn_rt @psorajja @HamidNadira @vonBardelebenRS @PhilippLurz @AbbottCardio @DoctorKini @KHERA_MD @LucySafi @ParasuramMD abbott.mediaroom.com/2024-04-02-Abb…

FIH SESAME data now out in #JACC: bit.ly/4c98Uo3 Transcatheter myotomy for oHCM and pre-TMVR @AdamGreenbaumMD @BabaliarosArgos @TheBethesdaLabs @jamiemccabeMD

Our analysis of @VizientInc data shows that acute MI events after TAVR are rare. Revascularization rates similar in post-TAVR AMI patients vs. all-comer AMI. Excited to be presenting results at #ACC24 with sim pub in @JACCJournals. Link: tinyurl.com/2t7pt3t8 @HarryDauerman

I'm glad @harvardmed sees what we see in @EricSecemskyMD. An amazing researcher, mentor and friend. Congrats!